Company Announcements

PASADENA, Calif.--(BUSINESS WIRE)--Feb. 23, 2026-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at multiple upcoming investor conferences:

• TD Cowen 46th Annual Health Care Conference
  Date: Monday, March 2, 2026
  Presentation Time: 3:50 p.m. ET / 12:50 p.m. PT
  
  
• Leerink Partners 2026 Global Healthcare Conference
  Date: Tuesday, March 10, 2026
  Presentation Time: 10:00 a.m. ET / 7:00 a.m. PT
  
  
• Barclays 28th Annual Global Healthcare Conference
  Date: Wednesday, March 11, 2026
  Presentation Time: 11:30 a.m. ET / 8:30 a.m. PT
  
  

Live webcasts of the presentations will be available under “Events & Presentations” in the Investors section of the Company’s website located at www.xencor.com. Replays of the events will be available on the Xencor website for at least 30 days following the presentations.

About Xencor

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223328030/en/

Charles Liles
cliles@xencor.com
(626) 737-8118

Source: Xencor, Inc.